Tonix Pharmaceuticals

Tonix is developing innovative pharmaceutical products to address public health challenges, with two therapeutic programs focusing on posttraumatic stress disorder (PTSD).

TNX-102 SL or Tonmya® is Tonix’s lead product candidate, designed as a bedtime treatment for PTSD, is currently in Phase 3 study in the military-related PTSD population. TNX-601 (tianeptine oxalate), designed as a daytime treatment for PTSD, is in preclinical development. PTSD is a serious condition characterized by chronic disability, inadequate treatment options especially for military-related PTSD and overall high utilization of healthcare services creating significant economic burden. Other products in development include TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage, to be developed as a potential smallpox-preventing vaccine.

The proposed trade name Tonmya (ton-MY-ah), for TNX-102 SL for the management of PTSD, has been conditionally accepted by the U.S. Food and Drug Administration (FDA).